GB Patent

GB2485291A — Cannabidiol (CBD) for use in the treatment of generalised and/or partial seizures

Assigned to GW Pharma Ltd · Expires 2012-05-09 · 14y expired

What this patent protects

Use of the phyto-cannabinoid cannabidiol (CBD) in the treatment of epilepsy and more particularly generalized (tonic-clonic) seizures and/or partial seizures. The daily dose of CBD is preferably at least 400 mg and more preferably 400-800 mg. CBD as an anticonvulsant may be used …

USPTO Abstract

Use of the phyto-cannabinoid cannabidiol (CBD) in the treatment of epilepsy and more particularly generalized (tonic-clonic) seizures and/or partial seizures. The daily dose of CBD is preferably at least 400 mg and more preferably 400-800 mg. CBD as an anticonvulsant may be used in combination with tetrahydrocannabivarin (THCV), wherein the daily dose of THCV is preferably at least 1.5 mg and more preferably at least 15 mg. CBD and THCV may be in the form of pure compounds or plant extracts with low contents of tetrahydrocannabinol (THC). The examples disclosed relate to the use of CBD (pure) or THCV (pure or botanical extract) as anti-epileptics.

Drugs covered by this patent

Patent Metadata

Patent number
GB2485291A
Jurisdiction
GB
Classification
—
Expires
2012-05-09
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.